Published in Cancer Weekly, October 27th, 1997
In test-tube cultures, the modified cells have already shown their ability to activate T cells within one week.
Penn investigators collaborated with a team from the National Cancer Institute in this ongoing research. The next step, the scientists say, will be to demonstrate that the dendritic cells can induce a clinically useful and safe response in the bodies of cancer patients.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.